NYSE:PHR - Phreesia Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.82
  • Forecasted Upside: 12.94 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$61.82
▼ -2.76 (-4.27%)

This chart shows the closing price for PHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phreesia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHR

Analyst Price Target is $69.82
▲ +12.94% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $69.82, with a high forecast of $81.00 and a low forecast of $50.00. The average price target represents a 12.94% upside from the last price of $61.82.

This chart shows the closing price for PHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 contributing investment analysts is to buy stock in Phreesia. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/7/2021Berenberg BankReiterated RatingBuy$75.00Medium
9/3/2021Raymond JamesBoost Price TargetOutperform$65.00 ➝ $75.00High
9/3/2021Robert W. BairdBoost Price TargetOutperform$62.00 ➝ $67.00High
9/2/2021Royal Bank of CanadaBoost Price TargetSector Perform$51.00 ➝ $60.00High
9/2/2021Needham & Company LLCBoost Price TargetBuy$70.00 ➝ $81.00High
8/27/2021Canaccord GenuityInitiated CoverageBuy$81.00High
7/13/2021JMP SecuritiesInitiated CoverageOutperform$80.00High
7/12/2021KeyCorpBoost Price TargetOverweight$70.00 ➝ $73.00High
6/17/2021JPMorgan Chase & Co.Boost Price TargetOverweight$64.00 ➝ $68.00Medium
6/8/2021Berenberg BankInitiated CoverageBuy$70.00High
6/7/2021Robert W. BairdBoost Price TargetOutperform$60.00 ➝ $62.00High
6/7/2021Piper SandlerBoost Price TargetOverweight$58.00 ➝ $63.50High
6/6/2021SVB LeerinkReiterated RatingBuyHigh
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
4/1/2021SVB LeerinkLower Price TargetOutperform$85.00 ➝ $75.00High
4/1/2021Robert W. BairdInitiated CoverageOutperform$60.00High
3/31/2021Piper SandlerReiterated RatingOverweight$56.00 ➝ $58.00High
3/31/2021KeyCorpLower Price TargetOverweight$80.00 ➝ $70.00Low
1/14/2021Needham & Company LLCBoost Price TargetBuy$60.00 ➝ $70.00High
12/14/2020Smith Barney CitigroupBoost Price Target$33.00 ➝ $59.00Low
12/10/2020Royal Bank of CanadaBoost Price TargetSector Perform$33.00 ➝ $51.00High
12/10/2020DA DavidsonBoost Price TargetBuy$35.00 ➝ $70.00High
12/10/2020SVB LeerinkBoost Price TargetOutperform$37.00 ➝ $62.00High
12/9/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $56.00High
12/9/2020Needham & Company LLCBoost Price TargetBuy$44.00 ➝ $60.00Medium
12/4/2020KeyCorpBoost Price TargetOverweight$37.00 ➝ $50.00High
11/10/2020StephensInitiated CoverageOverweight$50.00Medium
10/27/2020Needham & Company LLCInitiated CoverageBuy$44.00Low
10/23/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$32.00 ➝ $44.00Low
9/22/2020DA DavidsonInitiated CoverageBuy$35.00Low
9/10/2020Raymond JamesBoost Price TargetOutperform$35.00 ➝ $36.00High
9/10/2020SVB LeerinkBoost Price TargetOutperform$31.00 ➝ $37.00Medium
9/9/2020Piper SandlerBoost Price TargetOverweight$34.00 ➝ $35.00Medium
9/3/2020Raymond JamesReiterated RatingBuyLow
7/14/2020CitigroupInitiated CoverageNeutral$32.00Low
6/10/2020Raymond JamesBoost Price TargetOutperform$30.00 ➝ $35.00High
6/9/2020KeyCorpBoost Price TargetOverweight$34.00 ➝ $37.00High
5/20/2020KeyCorpBoost Price TargetOverweight$25.00 ➝ $34.00High
5/15/2020GuggenheimInitiated CoverageBuy$31.00Medium
4/24/2020Raymond JamesLower Price TargetOutperform$33.00 ➝ $30.00Low
4/24/2020Robert W. BairdBoost Price TargetOutperform$26.00 ➝ $28.00Low
4/24/2020Wells Fargo & CompanyLower Price TargetOverweight$35.00 ➝ $30.00High
4/20/2020Royal Bank of CanadaInitiated CoverageSector Perform$21.00Low
4/13/2020SVB LeerinkInitiated CoverageOutperform$24.00Medium
4/8/2020Robert W. BairdLower Price TargetOutperform$31.00 ➝ $26.00High
3/31/2020KeyCorpLower Price TargetOverweight$36.00 ➝ $25.00High
1/30/2020KeyCorpInitiated CoverageOverweight$36.00Low
1/8/2020Cantor FitzgeraldInitiated CoverageOverweight$32.00Medium
12/19/2019Raymond JamesInitiated CoverageOutperform$33.00Low
10/10/2019Robert W. BairdInitiated CoverageOutperform$31.00High
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$33.00Low
8/13/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$33.00Low
8/12/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$23.00High
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$33.00High
8/12/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$33.00Low
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/28/2021

Current Sentiment

  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Phreesia logo
Phreesia, Inc. is a healthcare software company, which engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products. Its solutions include health systems, multi-specialty, and federally qualified health centers (FQHCs). The company was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in New York, NY.
Read More

Today's Range

Now: $61.82
Low: $61.80
High: $63.23

50 Day Range

MA: $67.61
Low: $62.69
High: $72.12

52 Week Range

Now: $61.82
Low: $28.84
High: $81.59

Volume

3,829 shs

Average Volume

455,812 shs

Market Capitalization

$3.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Phreesia?

The following sell-side analysts have issued stock ratings on Phreesia in the last twelve months: Berenberg Bank, Canaccord Genuity, DA Davidson, JMP Securities, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, Stephens, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for PHR.

What is the current price target for Phreesia?

14 Wall Street analysts have set twelve-month price targets for Phreesia in the last year. Their average twelve-month price target is $69.82, suggesting a possible upside of 8.1%. Canaccord Genuity has the highest price target set, predicting PHR will reach $81.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $50.00 for Phreesia in the next year.
View the latest price targets for PHR.

What is the current consensus analyst rating for Phreesia?

Phreesia currently has 1 hold rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PHR will outperform the market and that investors should add to their positions of Phreesia.
View the latest ratings for PHR.

What other companies compete with Phreesia?

How do I contact Phreesia's investor relations team?

Phreesia's physical mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The company's listed phone number is (888) 654-7473 and its investor relations email address is [email protected] The official website for Phreesia is www.phreesia.com.